수혈대체 치료의 비용 효과
혈액학과
Early intravenous iron administration in the Emergency Department reduces red blood cell unit transfusion, hospitalisation, re-transfusion, length of stay and costs. (새로운 창 열기)
Source: Blood Transfus 2020;18(2):106-16.
Indexed: PubMed 31855149
DOI: 10.2450/2019.0248-19
Hemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in Europe. (새로운 창 열기)
Source: Support Care Cancer 2013;21(2):485-93.
Indexed: PubMed 22825456
DOI: 10.1007/s00520-012-1538-0
Restrictive blood transfusion practices are associated with improved patient outcomes. (새로운 창 열기)
Source: Transfusion 2014;54(10 Pt 2):2753-9.
Indexed: PubMed 24995770
DOI: 10.1111/trf.12723
Modeling the cost-effectiveness of prothrombin complex concentrate compared with fresh frozen plasma in emergency warfarin reversal in the United Kingdom. (새로운 창 열기)
Source: Clin Ther 2010;32(14):2478-93.
Indexed: PubMed 21353116
DOI: 10.1016/j.clinthera.2011.01.011
Recombinant activated factor VII use in critically ill infants with active hemorrhage. (새로운 창 열기)
Source: J Pediatr Surg 2008;43(12):2235-8.
Indexed: PubMed 19040942
DOI: 10.1016/j.jpedsurg.2008.08.053
Cost-effectiveness of eltrombopag vs intravenous immunoglobulin for the perioperative management of immune thrombocytopenia. (새로운 창 열기)
Source: Blood Adv. 2022;6(3):785-92.
Indexed: PubMed 34781363
DOI: 10.1182/bloodadvances.2021005627
Blood use in patients receiving intensive chemotherapy for acute leukemia or hematopoietic stem cell transplantation: the impact of a health system-wide patient blood management program. (새로운 창 열기)
Source: Transfusion 2017;57(9):2189-96.
Indexed: PubMed 28671296
DOI: 10.1111/trf.14191
Impact of a conservative red blood cell transfusion strategy in children undergoing hematopoietic stem cell transplantation. (새로운 창 열기)
Source: Biol Blood Marrow Transplant 2012;18(5):813-7.
Indexed: PubMed 22080050
DOI: 10.1016/j.bbmt.2011.10.043
The cost of blood: a study of the total cost of red blood cell transfusion in patients with β-thalassemia using time-driven activity-based costing. (새로운 창 열기)
Source: Transfusion 2019;59(11):3386-95.
Indexed: PubMed 31664712
DOI: 10.1111/trf.15558
Implementation of a patient blood management monitoring and feedback program significantly reduces transfusions and costs. (새로운 창 열기)
Source: Transfusion 2015;55(12):2807-15.
Indexed: PubMed 26264557
DOI: 10.1111/trf.13260
Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (새로운 창 열기)
Source: Cancer 2013;119(1):107-14.
Indexed: PubMed 22744794
DOI: 10.1002/cncr.27686
Budget impact analysis on erythropoiesis-stimulating agents use for the management of chemotherapy-induced anaemia in Greece. (새로운 창 열기)
Source: Cost Eff Resour Alloc 2013;11(1):16.
Indexed: PubMed 23870502
DOI: 10.1186/1478-7547-11-16
Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. (새로운 창 열기)
Source: Support Care Cancer 2012;20(1):159-65.
Indexed: PubMed 21359879
DOI: 10.1007/s00520-010-1083-7
Comparative net cost impact of the utilization of romiplostim and intravenous immunoglobulin for the treatment of patients with immune thrombocytopenia in Québec, Canada. (새로운 창 열기)
Source: J Med Econ 2013;16(2):318-26.
Indexed: PubMed 23216012
DOI: 10.3111/13696998.2012.756400
Blood transfusion versus hydroxyurea in beta-thalassemia in Iran: a cost-effectiveness study. (새로운 창 열기)
Source: Hematology 2018;23(7):417-22.
Indexed: PubMed 29157136
DOI: 10.1080/10245332.2017.1404262
The burden of blood transfusion: a utilization and economic analysis--a pilot study in patients with chemotherapy-induced anemia (CIA). (새로운 창 열기)
Source: J Med Econ 2013;16(5):633-8.
Indexed: PubMed 23425291
DOI: 10.3111/13696998.2013.778269
Prospective monitoring of plasma and platelet transfusions in a large teaching hospital results in significant cost reduction. (새로운 창 열기)
Source: Transfusion 2010;50(2):487-92.
Indexed: PubMed 19804569
DOI: 10.1111/j.1537-2995.2009.02413.x
Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease. (새로운 창 열기)
Source: Am J Hematol 2010;85(10):795-7.
Indexed: PubMed 20645429
DOI: 10.1002/ajh.21772
Increased hospital costs associated with red blood cell transfusion. (새로운 창 열기)
Source: Transfusion 2015;55(5):1082-9.
Indexed: PubMed 25488623
DOI: 10.1111/trf.12958